The demand for keloid treatment in Japan is projected to grow from USD 189.3 million in 2025 to USD 250.7 million by 2035, at a CAGR of 2.9%. Intralesional Corticosteroid Injections will dominate with a 22.0% market share, while hospitals will lead the end user segment with a 45.0% share.